Synthetic Biologics is a pioneering biotechnology company focused on developing innovative therapeutics that protect and preserve the gut microbiome, which is crucial for overall health. The company operates in the healthcare and biotechnology market, serving patients, healthcare providers, and researchers. Its business model revolves around research and development (R&D) of microbiome-based therapies, with a strong emphasis on clinical trials and scientific validation. Revenue is generated through the commercialization of its therapeutic candidates, licensing agreements, and potential partnerships with pharmaceutical companies. Synthetic Biologics is currently advancing two lead candidates poised for Phase 3 development, demonstrating its commitment to groundbreaking microbiome research. The company's team comprises industry leaders with extensive experience in R&D, clinical trials, manufacturing, and commercialization. By focusing on the microbiome, Synthetic Biologics aims to restore patient health and improve overall well-being.

Keywords: microbiome, therapeutics, gut health, biotechnology, clinical trials, R&D, healthcare, patient care, commercialization, innovation.